Advertisement
Screener

Scilex Holding Company (SCLX) P/E Ratio

2.8 / 5 stars · 68/120 Roast Me

Scilex Holding Co PE Ratio

The price-to-earnings (P/E) ratio tells you how many dollars investors pay for each dollar of a company's annual profit. It is market capitalization divided by net income over the trailing four quarters, meaning the four most recent filed quarters added together, and the table shows both amounts. A higher P/E means investors are paying more for each dollar of current earnings, often because they expect profits to grow; a negative P/E means the company lost money over those four quarters. Each point uses the filed share count and the last closing price on or before that quarter-end date, never today's price.

  • Scilex Holding Co pe ratio for the quarter ending 2026-06-30 was -0.14, a change of 0.36 year-over-year.
  • Scilex Holding Co pe ratio for the quarter ending 2026-03-31 was -0.12, a change of 17.6 year-over-year.
  • Scilex Holding Co pe ratio for the quarter ending 2025-12-31 was -0.23, a change of 0.44 year-over-year.
  • Scilex Holding Co pe ratio for the quarter ending 2025-09-30 was -0.41, a change of 43.65 year-over-year.
  • Scilex Holding Co pe ratio for fiscal 2026 was -0.14.
  • Scilex Holding Co pe ratio for fiscal 2025 was -0.23, a change of 0.44 from fiscal 2024.
  • Scilex Holding Co pe ratio for fiscal 2024 was -0.67, a change of 38.22 from fiscal 2023.
  • Scilex Holding Co pe ratio for fiscal 2023 was -38.89, a change of 487.17 from fiscal 2022.
Available history
2021-12-31 to 2026-06-30
Data captured

Historical PE Ratio

DatePE RatioMarket capitalizationNet income 12 month
2026-06-30-0.14$66.61M-$464.56M
2026-03-31-0.12$46.63M-$393.62M
2025-12-31-0.23$86.26M-$374.05M
2025-09-30-0.41$136.82M-$334.41M
2025-06-30-0.51$41.01M-$80.98M
2025-03-31-17.72$1.32B-$74.51M
2024-12-31-0.67$48.6M-$72.81M
2024-09-30-44.06$3.87B-$87.75M
2024-06-30-64.1$7.62B-$118.89M
2024-03-31-53.34$5.76B-$107.96M
2023-12-31-38.89$4.45B-$114.33M
2023-09-30-41.04$4.55B-$110.82M
2023-06-30-330.61$17.78B-$53.79M
2023-03-31-579.34$26.06B-$44.97M
2022-12-31-526.07$12.29B-$23.36M
2022-09-30-31.71$2.97B-$93.55M
2022-06-30-32.98$3.84B-$116.5M
2022-03-31-38.7$3.83B-$98.9M
2021-12-31-328.76$29.07B-$88.42M

Annual PE Ratio

DatePE RatioMarket capitalizationNet income 12 month
2026-06-30-0.14$66.61M-$464.56M
2025-12-31-0.23$86.26M-$374.05M
2024-12-31-0.67$48.6M-$72.81M
2023-12-31-38.89$4.45B-$114.33M
2022-12-31-526.07$12.29B-$23.36M
2021-12-31-328.76$29.07B-$88.42M

Similar stocks

Stock NameCountryMarket CapPE Ratio
Metagenomi Therapeutics, Inc. (MGX)United States$0.044B-0.48
LeonaBio, Inc. (LONA)United States$0.047B-0.61
Instil Bio, Inc. (TIL)United States$0.048B-1.73
Tevogen Inc. (TVGN)United States$0.049B
aTYR PHARMA INC (ATYR)United States$0.033B-0.98
Quince Therapeutics, Inc. (QNCX)United States$0.031B
CEL SCI CORP (CVM)United States$0.030B-0.81
Inmune Bio, Inc. (INMB)United States$0.056B-2.48
ImageneBio, Inc. (IMA)United States$0.056B-1.31
BioAtla, Inc. (BCAB)United States$0.058B-0.21